Clinical trial NCT04585815: Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Official title: A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Non-Small-Cell Lung Carcinoma
NSCLC
non small cell lung cancer
non-small cell lung cancer
BRAF mutation
BRAF V600e
BRAF
B-RAF NSCLC
lung cancer
immunotherapy
sasanlimab
encorafenib
binimetinib
axitinib
SEA-TGT
TIGIT
locally advanced
metastatic
ECOG 0
ECOG 1
Stage 3B
Stage IV
previously untreated
second-line therapy
first-line therapy
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2020-10-14
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study.

Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination.

Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated.

Sub-study B is complete. All participants have discontinued treatment and any additional follow up required by protocol.

Detailed description: Landscape 1011 is a clinical research study for people with advanced (stage 3b or 4) non-small cell lung cancer (NSCLC). The purpose of this study is to learn if the study medicine (sasanlimab, a type of immunotherapy) along with other study medicines is safe and effective in people with non-small cell lung cancer that has spread outside of the lungs. There are currently two sub-studies using different types of medicines. People in the first sub-study will receive sasanlimab as a subcutaneous (under the skin) injection at the study clinic every 4 weeks. Additionally, they will take targeted cancer therapies encorafenib by mouth once a day and binimetinib by mouth twice a day at home.

People in the second sub-study will receive the study medicine sasanlimab as a subcutaneous (under the skin) injection at the study clinic every 3 weeks and will also receive SEA-TGT (an immunotherapy) by infusion every three weeks.

Additionally, they will take axitinib (a targeted therapy) by mouth twice a day at home.

In addition to taking the study drugs, participants in the sub-studies will be asked to visit the clinic for health checks. These include health questions, physical examinations, blood and urine samples, and imaging scans. These assessments help the study doctor and team to monitor the participants' safety and well-being, and to see how their cancer is responding to the treatment. Participants will continue in the study until the cancer is no longer responding to the study medicine.

Eligibility criteria: Inclusion Criteria Umbrella Phase 1b \& 2:

* Histologically or cytologically confirmed locally advanced/metastatic (Stage IIIB-IV) NSCLC.
* At least one measurable lesion per RECIST v1.1 at Screening.
* ECOG Performance Status 0 or 1.
* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.
* Adequate hepatic, renal, and bone marrow function.

Additional Inclusion Criteria for Sub-Study A Phase 1b \&2:

-BRAFV600E mutation in tumor tissue or plasma as determined by a local laboratory PCR or NGS assay and documented in a local pathology report.

Additional Inclusion Criteria for Sub-Study A Phase 1b only:

-Any line of therapy for locally advanced/metastatic NSCLC.

Additional Inclusion Criteria for Sub-Study A Phase 2 only:

-Previously untreated for locally advanced/metastatic NSCLC

Additional Inclusion Criteria for Sub-Study B Phase 1b only::

-Any line of therapy for locally advanced/metastatic NSCLC.

Additional Inclusion Criteria for Sub-Study B Phase 2 only:

* Previously untreated for locally advanced/metastatic NSCLC (Arms B1 \& B2), or
* One or 2 prior lines of therapy for advanced/metastatic NSCLC (Arm B3), including immune checkpoint inhibitor treatment + chemotherapy, and have progressed during or after that therapy.
* PD-L1 TPS ≥1%

Exclusion Criteria Umbrella Phase 1b \&2:

* Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent.
* Active non-infectious pneumonitis, pulmonary fibrosis, or known history of immune-mediated pneumonitis.
* Active infection requiring systemic therapy.
* Clinically significant cardiovascular disease.
* Other malignancy within 2 years of first dose, with exceptions.
* Symptomatic brain metastasis, with exceptions.

Additional Exclusion Criteria for Sub-Study A Phase 1b\&2:

* EGFR mutation, ALK fusion oncogene, or ROS1 rearrangement.
* Prior treatment with any BRAF inhibitor or MEK inhibitor.

Additional Exclusion Criteria for Sub-Study A Phase 2 only:

-Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents.

Additional Exclusion Criteria for Sub-Study B Phase 1b\&2:

-Documentation of any tumor-driving molecular alteration (eg, BRAF, EGFR, ALK)

Additional Exclusion Criteria for Sub-Study B Phase 2 only:

* Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents.(Arms B1 \& B2)
* Confirmed progressive disease on 1st or 2nd imaging tumor assessment after initiation of therapy for advanced/metastatic NSCLC.

Primary outcomes:
measure: Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT)
timeFrame: Day 1 up to Day 28 of Cycle 1
measure: Phase 2 of Sub-Study A: Durable Objective Response Rate (ORR)
timeFrame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy
measure: Phase 1b of Sub-Study B: Percentage of Participants With DLT
timeFrame: Day 1 up to Day 21 of Cycle 1
measure: Phase 2 Sub-Study B: Objective Response Rate
timeFrame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)
Secondary outcomes:
measure: Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
timeFrame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (approximately 44 months)
measure: Phase 2 of Sub-Study A: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0
timeFrame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment
measure: Phase 1b of Sub-Study A: Number of Participants With Laboratory Abnormalities
timeFrame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (approximately 44 months)
measure: Phase 2 of Sub-Study A: Number of Participants With Laboratory Abnormalities
timeFrame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment
measure: Phase 1b of Sub-Study A: Durable Objective Response Rate
timeFrame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (approximately 44 months)
measure: Phase 1b of Sub-Study A: Objective Response Rate
timeFrame: From the date of first dose of study treatment until the date of the first documentation of PD (approximately 44 months)
measure: Phase 2 of Sub-Study A: Objective Response Rate
timeFrame: From the date of first dose of study treatment until the date of the first documentation of PD
measure: Phase 2 of Sub-Study A: Duration of Response (DR)
timeFrame: From the date of first documentation of OR to the date of the first documentation of PD or death due to any cause, whichever occurred first
measure: Phase 2 of Sub-Study A: Time to Tumor Response (TTR)
timeFrame: From the date of first dose of study treatment to the date of first documentation of objective response
measure: Phase 2 of Sub-Study A: Progression-Free Survival (PFS)
timeFrame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first
measure: Phase 2 of Sub-Study A: Overall Survival (OS)
timeFrame: From the date of first dose of study treatment to the date of death due to any cause or censoring date
measure: Phase 1b of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab
timeFrame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8] and 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days)
measure: Phase 2 of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab
timeFrame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days)
measure: Phase 1b of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab
timeFrame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8],336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days)
measure: Phase 2 of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab
timeFrame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
measure: Phase 1b of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab
timeFrame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8], 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days)
measure: Phase 2 of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab
timeFrame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
measure: Phase 1b of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
timeFrame: Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
measure: Phase 2 of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
timeFrame: Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
measure: Phase 1b of Sub-Study A: Ctrough of Encorafenib
timeFrame: Day 1 (pre-dose) of Cycle 1, 2 and 5; Day 15 of Cycle 1 (1 cycle= 28 days)
measure: Phase 2 of Sub-Study A: Ctrough of Encorafenib
timeFrame: Cycle 5 Day 1 (pre-dose)
measure: Phase 1b of Sub-Study A: Ctrough of Binimetinib
timeFrame: Day 1 (pre-dose) of Cycles 1, 2, and 5 (1 cycle= 28 days)
measure: Phase 2 of Sub-Study A: Ctrough of Binimetinib
timeFrame: Cycle 5 Day 1 (pre-dose)
measure: Phase 1b of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab
timeFrame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 255 days) (1 cycle= 28 days)
measure: Phase 2 of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab
timeFrame: Pre-dose on Cycle 1 Day 1 until end of treatment
measure: Phase 2 of Sub-Study A: Objective Response (OR) Rate by Programmed Death Ligand-1 (PD-L1) Expression at Baseline
timeFrame: From the date of first dose of study treatment until the date of the first documentation of PD
measure: Phase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) Score
timeFrame: Baseline up to end of treatment
measure: Phase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) Score
timeFrame: Baseline up to end of treatment
measure: Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0
timeFrame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum of 21 months)
measure: Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0
timeFrame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum of 21 months)
measure: Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0
timeFrame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum of 21 months)
measure: Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0
timeFrame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum of 21 months)
measure: Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0
timeFrame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum of 21 months)
measure: Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0
timeFrame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum of 21 months)
measure: Phase 1b of Sub-Study B: Objective Response Rate (ORR)
timeFrame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy, whichever occurred first (maximum of 21 months)
measure: Phase 1b of Sub-Study B: Duration of Response (DR)
timeFrame: From the date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months)
measure: Phase 1b of Sub-Study B: Time to Tumor Response (TTR)
timeFrame: From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months)
measure: Phase 1b of Sub-Study B: Progression-Free Survival (PFS)
timeFrame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months)
measure: Phase 2 of Sub-Study B: Duration of Response (DR)
timeFrame: From date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months)
measure: Phase 2 of Sub-Study B: Time to Tumor Response (TTR)
timeFrame: From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months)
measure: Phase 2 of Sub-Study B: Progression-Free Survival (PFS)
timeFrame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months)
measure: Phase 2 of Sub-Study B: Overall Survival (OS)
timeFrame: From the date of first dose of study treatment to the date of death due to any cause or censoring date, whichever occurred first (maximum of 21 months)
measure: Phase 1b of Sub-Study B: Cmax of Sasanlimab
timeFrame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
measure: Phase 1b of Sub-Study B: Cmax of Axitinib
timeFrame: Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days)
measure: Phase 1b of Sub-Study B: Cmax of SEA-TGT
timeFrame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
measure: Phase 2 of Sub-Study B: Cmax of Sasanlimab
timeFrame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
measure: Phase 2 of Sub-Study B: Cmax of Axitinib
timeFrame: Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days)
measure: Phase 2 of Sub-Study B: Cmax of SEA-TGT
timeFrame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
measure: Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
timeFrame: Pre-dose on Cycle 1 Day 1 and Cycle 5 Day 1 (1 cycle= 21 days)
measure: Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib
timeFrame: Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days)
measure: Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT
timeFrame: Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days)
measure: Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
timeFrame: Cycle 1: pre-dose on Day 1, Cycle 5: pre-dose on Day 1 (1 cycle= 21 days)
measure: Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib
timeFrame: Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days)
measure: Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT
timeFrame: Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days)
measure: Phase 1b of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT
timeFrame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days)
measure: Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT
timeFrame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days)
measure: Phase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue
timeFrame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope Investigational Drug Services (IDS)
state: California
city: Duarte
country: United States
facility: City of Hope
state: California
city: Encinitas
country: United States
facility: UCSD Medical Center - Encinitas
state: California
city: Fresno
country: United States
facility: California Cancer Associates for Research and Excellence, Inc (cCARE)
state: California
city: Glendale
country: United States
facility: The Oncology Institute of Hope and Innovation
state: California
city: La Jolla
country: United States
facility: UC San Diego Moores Cancer Center - Investigational Drug Services
state: California
city: La Jolla
country: United States
facility: Koman Family Outpatient Pavilion
state: California
city: La Jolla
country: United States
facility: Sulpizio Cardiovascular Center at UC San Diego Health
state: California
city: La Jolla
country: United States
facility: UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
state: California
city: La Jolla
country: United States
facility: UCSD Perlman Medical Offices
state: California
city: La Jolla
country: United States
facility: UC San Diego Moores Cancer Center
state: California
city: Long Beach
country: United States
facility: The Oncology Institute of Hope and Innovation
state: California
city: Los Angeles
country: United States
facility: The Oncology Institute of Hope and Innovation
state: California
city: Los Angeles
country: United States
facility: USC/Norris Comprehensive Cancer Center
state: California
city: San Diego
country: United States
facility: UC San Diego Medical Center - Hillcrest
state: California
city: Santa Ana
country: United States
facility: The Oncology Institute of Hope and Innovation
state: California
city: Vista
country: United States
facility: UCSD Medical Center - Vista
state: California
city: Whittier
country: United States
facility: The Oncology Institute of Hope and Innovation
state: California
city: Colorado Springs
country: United States
facility: UCHealth Memorial Hospital Central
state: Colorado
city: Colorado Springs
country: United States
facility: UCHealth Memorial Hospital North
state: Colorado
city: Altamonte Springs
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Bonita Springs
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Bradenton
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Brandon
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Cape Coral
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Celebration
country: United States
facility: AdventHealth Celebration Infusion Center
state: Florida
city: Celebration
country: United States
facility: AdventHealth Medical Group Oncology Research at Celebration
state: Florida
city: Clearwater
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Gainesville
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Largo
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Lecanto
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Naples
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Ocala
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Orange City
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Orlando
country: United States
facility: Advent Health Orlando - Investigational Drug Services
state: Florida
city: Orlando
country: United States
facility: AdventHealth Orlando Infusion Center
state: Florida
city: Orlando
country: United States
facility: AdventHealth Orlando
state: Florida
city: Orlando
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Port Charlotte
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Saint Petersburg
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Sarasota
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Sarasota
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Spring Hill
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Tampa
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Tampa
country: United States
facility: Moffitt Cancer Center
state: Florida
city: Tavares
country: United States
facility: Florida Cancer Specialists
state: Florida
city: The Villages
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Trinity
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Venice
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Venice
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Winter Park
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Baltimore
country: United States
facility: University of Maryland Greenebaum Comprehensive Cancer Center
state: Maryland
city: Baltimore
country: United States
facility: University of Maryland Medical Center -IDS Pharmacy
state: Maryland
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Ophthalmic Consultants of Boston Inc (OCB)
state: Massachusetts
city: Dearborn
country: United States
facility: Henry Ford Medical Center - Fairlane
state: Michigan
city: Detroit
country: United States
facility: Henry Ford Hospital
state: Michigan
city: Novi
country: United States
facility: Henry Ford Medical Center - Columbus
state: Michigan
city: Morristown
country: United States
facility: Atlantic Health System / Morristown Medical Center
state: New Jersey
city: Morristown
country: United States
facility: Morristown Medical Center
state: New Jersey
city: Summit
country: United States
facility: Medical Diagnostic Associates
state: New Jersey
city: Summit
country: United States
facility: Overlook Medical Center
state: New Jersey
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai
state: New York
city: New York
country: United States
facility: Mount Sinai Hospital Pharmacy
state: New York
city: Dickson
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Franklin
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Gallatin
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Hendersonville
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Hermitage
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Lebanon
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Murfreesboro
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Nashville
country: United States
facility: Sarah Cannon Research Institute - Pharmacy
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Shelbyville
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Smyrna
country: United States
facility: Tennessee Oncology PLLC
state: Tennessee
city: Camperdown
country: Australia
facility: Chris O'Brien Lifehouse
state: New South Wales
city: Concord
country: Australia
facility: Concord Hospital
state: New South Wales
city: St Leonards
country: Australia
facility: GenesisCare North Shore
state: New South Wales
city: St Leonards
country: Australia
facility: North Shore Radiology and Nuclear Medicine
state: New South Wales
city: Heidelberg
country: Australia
facility: Austin Health
state: Victoria
city: Edegem
country: Belgium
facility: Antwerp University Hospital
state: Antwerpen
city: Gent
country: Belgium
facility: UZ Gent
city: Leuven
country: Belgium
facility: UZ Leuven
city: Taichung
country: Taiwan
facility: Chung Shan Medical University Hospital
city: Taipei City
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei City
country: Taiwan
facility: Koo Foundation Sun Yat -Sen Cancer Center
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: Koo Foundation Sun Yat-Sen Cancer Center
city: London
country: United Kingdom
facility: Sarah Cannon Research Institute UK
city: Newcastle upon Tyne
country: United Kingdom
facility: Royal Victoria Infirmary
city: Newcastle upon Tyne
country: United Kingdom
facility: Sir Bobby Robson Cancer Trials Research Centre
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: